Publication: Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants
Issued Date
2008-04-24
Resource Type
ISSN
0264410X
Other identifier(s)
2-s2.0-42449133708
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine. Vol.26, No.18 (2008), 2234-2241
Suggested Citation
Salvacion Gatchalian, Yafu Yao, Benli Zhou, Lei Zhang, Sutee Yoksan, Kim Kelly, Kathleen M. Neuzil, Mansour Yaïch, Julie Jacobson Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine. Vol.26, No.18 (2008), 2234-2241. doi:10.1016/j.vaccine.2008.02.042 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/19339
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants
Other Contributor(s)
Abstract
Japanese encephalitis (JE) virus is a major cause of disease, disability, and death in Asia. An effective, live, attenuated JE vaccine (LJEV) is available; however, its use in routine immunization schedules is hampered by lack of data on concomitant administration with measles vaccine (MV). This study evaluated the immunogenicity and reactogenicity of LJEV and MV when administered at the same or separate study visits in infants younger than 1 year of age. Three groups of healthy infants were randomized to receive LJEV at age of 8 months and MV at 9 months (Group 1; n = 100); MV and LJEV together at 9 months (Group 2; n = 236); or MV and LJEV at 9 and 10 months, respectively (Group 3; n = 235). Blood was obtained 4 weeks after each vaccine administration to determine antibody levels for measles and JE. Reactogenicity was assessed by parental diaries and clinic visits. Four weeks after immunization, measles seroprotection rates (defined as ≥340 mIU/ml) were high and comparable in all three groups and specifically, rates in the combined MV-LJEV (Group 2) were not statistically inferior to those in Group 3 receiving MV separately (96% versus 100%, respectively). Likewise, the LJEV seroprotection rates were high and similar between the three groups. The reactogenicity profiles of the three vaccine schedules were also analogous. LJEV and MV administered together are well tolerated and immunogenic in infants younger than 1 year. These results should facilitate incorporation of LJEV into routine immunization schedules with MV. © 2008 Elsevier Ltd. All rights reserved.